Otsuka Pharmaceuticals

What Otsuka Pharmaceuticals does

Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) are the US operations of Otsuka Pharmaceutical Co., Ltd., a Japanese healthcare conglomerate publicly traded on the Tokyo Stock Exchange (Ticker 4578) that operates 183 affiliated companies across 28 countries. Otsuka's US business focuses on three therapeutic areas: central nervous system (CNS) and serious mental illness, nephrology and immunology, and rare disease. The US portfolio includes marketed pharmaceutical products ABILIFY (aripiprazole), ABILIFY MAINTENA, ABILIFY ASIMTUFII, ABILIFY MYCITE (with digital sensor), REXULTI (brexpiprazole), JYNARQUE (tolvaptan, the only FDA-approved treatment to slow kidney function decline in ADPKD), SAMSCA (tolvaptan), NUEDEXTA, IV BUSULFEX, and the newly approved VOYXACT (sibeprenlimab-szsi) for primary IgA nephropathy. The investigational pipeline includes centanafadine (a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor under FDA Priority Review for ADHD), TSND-201/methylone (a Breakthrough Therapy-designated rapid-acting neuroplastogen for PTSD, acquired via Transcend Therapeutics), and repinatrabit/JNT-517 (an investigational PKU treatment acquired via Jnana Therapeutics).

Otsuka's underlying science spans humanized monoclonal antibodies with novel mechanisms (APRIL inhibition without B-cell depletion), first-in-class small-molecule reuptake inhibitors, neuroplastogens, and psychedelic-inspired serotonergic agonists. Beyond small molecules and biologics, Otsuka co-developed Rejoyn with Click Therapeutics, the first FDA-authorized digital prescription therapeutic for major depressive disorder. Manufacturing complies with FDA cGMP, and products are distributed through authorized distributors of record including McKesson, Cardinal Health, Cencora, Morris & Dickson, specialty biologic channels for JYNARQUE, patient support services through EVERSANA, the Otsuka Patient Assistance Foundation for uninsured/underinsured patients, and direct Asia-Pacific licensing (e.g., 4D Molecular Therapeutics for 4D-150).

Otsuka's revenue model is pharmaceutical product sales through enterprise field sales teams targeting nephrologists, psychiatrists, and hospitals, supplemented by medical science liaisons, patient advocacy programs, and digital therapeutic collaborations. End customers are physicians, healthcare institutions, and indirectly patients with CNS conditions, kidney disease, and rare autoimmune disorders, with caregiver-oriented product education and a network of professional communities (PsychU, NephU, Society of Valued Minds) supporting brand engagement. Pricing is not publicly disclosed and is negotiated through healthcare providers, insurers, and government programs. US headquarters are at 508 Carnegie Center Dr, Princeton, NJ, with additional offices in Rockville, MD and Hayward, CA, plus the recently acquired Transcend Therapeutics subsidiary in New York City.

Name

Otsuka Pharmaceuticals

Legal name

Otsuka America Pharmaceutical, Inc.

Website

https://otsuka-us.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Otsuka America Pharmaceutical, Inc., the US subsidiary of Japan's Otsuka Pharmaceutical Co., Ltd., is a CNS, nephrology, and immunology-focused pharmaceutical company that develops, manufactures, and distributes FDA-approved drugs including VOYXACT for IgA nephropathy, JYNARQUE for ADPKD, ABILIFY, and REXULTI for serious mental illness, serving US patients, healthcare providers, and caregivers.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Ophthalmic & Otic Generics (HLAIABAF)

Keywords

• Prescription pharmaceuticals
• Central nervous system therapeutics
• Nephrology treatments
• Immunology drugs
• Digital therapeutics

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Otsuka generates revenue through the sale of FDA-approved pharmaceutical products including ABILIFY (aripiprazole), ABILIFY MAINTENA, ABILIFY ASIMTUFII, JYNARQUE (tolvaptan), SAMSCA (tolvaptan), NUEDEXTA, REXULTI (brexpiprazole), IV BUSULFEX, and VOYXACT (sibeprenlimab-szsi). Products are distributed through authorized wholesalers, distributors, and specialty pharmacies.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels9 records

Core offering

Otsuka Pharmaceuticals (Otsuka America Pharmaceutical, Inc.) is a US-based pharmaceutical company that develops, manufactures, and commercializes FDA-approved prescription drugs across three core therapeutic areas: central nervous system (CNS) disorders, nephrology, and immunology. Its marketed portfolio includes ABILIFY/ABILIFY MAINTENA/ABILIFY ASIMTUFII (aripiprazole), REXULTI (brexpiprazole), JYNARQUE and SAMSCA (tolvaptan), IV BUSULFEX (busulfan), NUEDEXTA, and the recently approved VOYXACT (sibeprenlimab-szsi). The company also co-developed Rejoyn, the first FDA-authorized digital prescription therapeutic for major depressive disorder, and maintains a pipeline targeting ADHD, PTSD, and phenylketonuria.

Product overview

Otsuka Pharmaceutical is a total healthcare company with two main business segments: medical-related business (treatments and diagnostics for physical and mental health) and nutraceutical business (daily health maintenance products). Otsuka's US companies focus on neuroscience, nephrology, and immunology therapeutic areas. The product portfolio includes FDA-approved pharmaceutical products such as VOYXACT (sibeprenlimab-szsi) for IgA nephropathy, ABILIFY (aripiprazole) and REXULTI (brexpiprazole) for psychiatric conditions, JYNARQUE and SAMSCA (tolvaptan) for kidney conditions and hyponatremia, and IV BUSULFEX for oncology. The investigational pipeline includes centanafadine (ADHD, NDA submitted with Priority Review), TSND-201 (PTSD, acquired via Transcend Therapeutics), and repinatrabit (PKU, acquired via Jnana Therapeutics). Additionally, Otsuka co-developed the FDA-approved digital therapeutic Rejoyn with Click Therapeutics for major depressive disorder.

Differentiator

Problem solved

Functional benefit

Brands

• VOYXACT (sibeprenlimab-szsi): FDA-approved selective APRIL inhibitor for IgA nephropathy
• NephU
• PsychU
• Society of Valued Minds (SoVM)
• Otsuka Patient Education Network (OPEN)
• NEXUS
• Global Council on Alzheimer's Disease (GCAD)

Products and services

• VOYXACT (sibeprenlimab-szsi) A humanized monoclonal antibody that selectively inhibits APRIL (A-PRoliferation-Inducing Ligand) to reduce pathogenic galactose-deficient IgA1 production, used to treat adults with primary IgA nephropathy (IgAN) at risk of disease progression. Self-administered subcutaneous injection dosed once every four weeks.
• ABILIFY (aripiprazole)

Quantifiable outcome

• VOYXACT showed mean eGFR change of +0.7 mL/min/1.73 m² vs -4.8 in placebo (treatment effect 5.5) over 12 months in IgAN patients
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

18 partnerships are on record, tiered core and minor.

• Transcend TherapeuticscoreStrategic or Co-development Partner · 12 June 2026Otsuka America, Inc. fully acquired Transcend Therapeutics (clinical-stage biotech, founded 2021, based in New York City) for $700 million at closing plus up to $525 million in contingent consideration based on future sales. Transcend operates as a wholly owned subsidiary. Its lead candidate TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD, received Breakthrough Therapy designation and is in Phase 3. The acquisition accelerates Otsuka's next-generation neuropsychiatric treatment portfolio.
• 4D Molecular TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 1 December 2025Otsuka Pharmaceuticals entered into an exclusive Asia-Pacific license agreement with 4D Molecular Therapeutics for 4D-150 therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Otsuka paid $85 million upfront with potential milestone payments up to $336 million.
• Caregiver Action NetworkminorGTM or Marketing Partner · 1 January 2025Otsuka partners with Caregiver Action Network, the nation's leading nonprofit family caregiver organization, to improve quality of life for caregivers through education, peer support, and resources.
• National Alliance for CaregivingminorGTM or Marketing Partner · 1 January 2025Otsuka collaborates with the National Alliance for Caregiving, a nonprofit coalition working to build health, wealth, and equity for family caregivers through research, advocacy, and system change programs.
• Alliance for Aging ResearchminorGTM or Marketing Partner · 1 January 2025Otsuka partners with the Alliance for Aging Research, which provides blog posts, videos, factsheets, and news updates valuable to those caring for aging loved ones.
• Columbia University Mailman School of Public HealthminorStrategic or Co-development Partner · 1 January 2025Otsuka sponsored research by Columbia University Mailman School of Public Health on the value of family caregiving, quantifying 44.58 million caregivers providing $873.5 billion in unpaid labor annually in the US.
• Society of Valued Minds (SoVM)minorGTM or Marketing Partner · 1 January 2025Otsuka co-founded Society of Valued Minds (SoVM), an initiative uniting young people to fight mental health stigma through self-expression.
• McKesson CorporationcoreChannel Partner/ Reseller/ Distributor · 1 January 2025McKesson Corporation is an authorized distributor of record for Otsuka products including ABILIFY, ABILIFY MAINTENA, ABILIFY ASIMTUFII, IV BUSULFEX, NUEDEXTA, REXULTI, and SAMSCA. McKesson Plasma & Biologics also distributes JYNARQUE as a specialty biologic.
• Cardinal Health, Inc.coreChannel Partner/ Reseller/ Distributor · 1 January 2025Cardinal Health is an authorized distributor of record for multiple Otsuka products. Cardinal Health Specialty Solutions provides third-party logistics for Otsuka, including distribution of ABILIFY MYCITE (digital medicine with sensor).
• CencoracoreChannel Partner/ Reseller/ Distributor · 1 January 2025Cencora (formerly AmerisourceBergen) is an authorized distributor of record for Otsuka pharmaceutical products including ABILIFY, ABILIFY MAINTENA, ABILIFY ASIMTUFII, IV BUSULFEX, NUEDEXTA, REXULTI, and SAMSCA.
• Morris & Dickson Co LLCcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Morris & Dickson Co LLC is an authorized distributor of record for Otsuka products including ABILIFY, ABILIFY MAINTENA, ABILIFY ASIMTUFII, IV BUSULFEX, NUEDEXTA, REXULTI, and SAMSCA.
• Otsuka Patient Assistance FoundationcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Otsuka Patient Assistance Foundation (OPAF) provides medication at no cost to eligible uninsured or underinsured patients for ABILIFY MAINTENA and JYNARQUE (tolvaptan), supporting patient access.
• EVERSANA Life SciencescoreChannel Partner/ Reseller/ Distributor · 1 January 2025EVERSANA Life Sciences provides patient support services and is listed as a patient support channel for Otsuka products including ABILIFY MAINTENA, JYNARQUE, NUEDEXTA, REXULTI, and SAMSCA.
• Jnana TherapeuticscoreStrategic or Co-development Partner · 1 September 2024Otsuka acquired Jnana Therapeutics in September 2024, bringing repinatrabit (JNT-517), an investigational treatment for phenylketonuria (PKU). Repinatrabit has received orphan drug designation and rare pediatric disease designation from the FDA. A pivotal global Phase 3 trial (PheORD) is underway.
• NEXUS (Mental Health Community)minorGTM or Marketing Partner · 1 January 2024Otsuka supports NEXUS, a community bridging gaps in mental health support with traditional and nontraditional mental health stakeholders focused on critical junctures in care.
• Global Council on Alzheimer's Disease (GCAD)minorGTM or Marketing Partner · 1 January 2024Otsuka collaborates across sectors through GCAD to move Alzheimer's disease care forward, including addressing agitation in Alzheimer's dementia.
• Mindset Pharma Inc.coreStrategic or Co-development Partner · 27 October 2023Otsuka America, Inc. completed the acquisition of Mindset Pharma Inc. for CAD 75.9 million (approximately CAD $80 million all-cash transaction), with deal closing on October 27, 2023. Mindset specialized in drug discovery for psychiatric and neurological disorders, particularly novel compounds and development efforts in serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD.
• Click TherapeuticscoreStrategic or Co-development Partner · 1 January 2023Otsuka Pharmaceutical co-developed Rejoyn with Click Therapeutics, the first FDA-authorized digital prescription therapeutic for major depressive disorder (MDD). The digital therapeutic was developed as an adjunct to antidepressant medication and evaluated in a Phase 3 randomized controlled trial (Mirai study).

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• H. Lundbeck A/S: Lundbeck is a Danish CNS-focused specialty pharmaceutical company with a US commercial presence (Trintellix, Rexulti co-promoted with Otsuka in some markets). Its CNS-exclusive portfolio, similar patient/HCP focus, and comparable geographic footprint make it the closest direct strategic peer to Otsuka's CNS franchise.
• Jazz Pharmaceuticals: Jazz is a specialty pharmaceutical company with significant CNS and neurology franchises (Xywav, Epidiolex, Sunosi). Its US commercial focus on neuroscience and rare/CNS disorders, along with specialty distribution and HCP-targeted sales motions, closely parallels Otsuka's CNS commercial model.
• Sumitomo Pharma: Sumitomo Pharma is a Japan-headquartered pharmaceutical group with a major CNS franchise (Latuda/lurasidone, loreclezole for Dravet). Like Otsuka, it is a Japanese parent operating significant US commercial assets in psychiatry, sharing therapeutic-area overlap and a similar cross-border commercial structure.
• Travere Therapeutics: Travere Therapeutics received accelerated FDA approval for Filspari (sparsentan) in IgA nephropathy, directly competing with Otsuka's VOYXACT in the same indication. Its IgAN-focused pipeline and similar nephrology distribution approach make it the most direct competitive peer for Otsuka's newest launch.
• Calliditas Therapeutics: Calliditas developed Nefecon (targeted-release budesonide), the first FDA-approved treatment for IgA nephropathy. Now part of Asahi Kasei, it competes head-to-head with VOYXACT in the US IgAN market and shares Otsuka's rare-disease nephrology positioning.
• Intra-Cellular Therapies (now Johnson & Johnson Innovative Medicine): Intra-Cellular Therapies developed Caplyta (lumateperone), a CNS agent overlapping with Otsuka's schizophrenia and depression adjacencies. Acquired by J&J in 2025, it represents a direct competitor whose Caplyta franchise has been gaining share against Otsuka's REXULTI and ABILIFY MAINTENA.

Broad incumbents

• Takeda Pharmaceutical: Takeda is a Japan-headquartered global pharmaceutical company with a large US commercial presence spanning CNS, GI, oncology, and rare disease. As a comparable Japanese pharma parent with significant US operations, it represents the closest broad-incumbent structural peer to Otsuka Pharmaceutical Co., Ltd.'s US footprint.
• Astellas Pharma: Astellas is a Japanese pharmaceutical company with global operations including US commercial sales across urology, oncology, and rare disease. Like Otsuka, it is a Japanese parent operating significant US assets through US subsidiaries, making it a comparable broad incumbent.
• Daiichi Sankyo: Daiichi Sankyo is a Japanese pharmaceutical company with growing US commercial operations in oncology, cardiovascular, and specialty care. Its Japanese parent / US subsidiary structure and pipeline breadth are structurally comparable to Otsuka's.
• AbbVie: AbbVie operates large franchises in psychiatry (Vraylar) and immunology, overlapping with Otsuka's CNS and immunology/rare-disease therapeutic areas. As a major US-focused commercial pharma, it competes with Otsuka for the same HCP audience and payer attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/OtsukaUS
• YouTubeyoutube.com/channel/UCSMEX6Q10v5ehZSKsN-Odwg
• Facebookfacebook.com/OtsukaUS
• LinkedInlinkedin.com/company/otsuka-pharmaceutical-companies
• Instagraminstagram.com/otsuka_us

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Pharmaceuticals